REFRACTORY EWING SARCOMA
Clinical trials for REFRACTORY EWING SARCOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY EWING SARCOMA trials appear
Sign up with your email to follow new studies for REFRACTORY EWING SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug tested for Tough-to-Treat childhood bone cancer
Disease control Recruiting nowThis study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose and checks for side effects, and the second part measures how well the drug shr…
Matched conditions: REFRACTORY EWING SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New hope for kids with Hard-to-Treat cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.
Matched conditions: REFRACTORY EWING SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …
Matched conditions: REFRACTORY EWING SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 06, 2026 16:01 UTC